Table 4 The effects of CoQ10 supplementation on lipid profiles with CI 95% by using subgroup analysis
Variables | Ka | I2 (%) | Q test | SMD (95% CI) | P-value |
|---|---|---|---|---|---|
TC | |||||
Total | 8 | 94.9 | 138.32 | −1.07 (−1.94, −0.21) | 0.015 |
Type of disease | |||||
HF | 3 | 0.00 | 0.04 | 0.16 (−0.15, 0.47) | 0.306 |
CAD | 5 | 96.7 | 122.87 | −2.01 (−3.43, −0.60) | 0.005 |
Type of intervention | |||||
Q10 | 6 | 84.7 | 32.72 | −0.32 (−0.85, 0.22) | 0.244 |
Q10 + other | 2 | 99.0 | 102.67 | −4.50 (−13.39, 4.39) | 0.321 |
Dosage of intervention (mg/dL) | |||||
≤ 150 | 5 | 96.3 | 107.92 | −1.53 (−2.83, −0.23) | 0.021 |
> 150 | 3 | 93.4 | 30.37 | −0.52 (−1.78, 0.73) | 0.414 |
Duration of study | |||||
< 8 weeks | 3 | 0.00 | 1.06 | 0.06 (−0.26, 0.39) | 0.707 |
≥ 8 weeks | 5 | 96.9 | 128.76 | −1.94 (−3.33, − 0.54) | 0.006 |
Sample size | |||||
≤ 50 person | 2 | 0.00 | 0.60 | −0.03 (− 0.44, 0.39) | 0.13 |
> 50 person | 6 | 96.3 | 135.05 | −1.52 (−2.67, − 0.37) | 2.59 |
LDL-C | |||||
Total | 6 | 82.8 | 29.05 | −0.37 (− 0.87, 0.13) | 0.149 |
Type of disease | |||||
HF | 3 | 91.8 | 24.47 | −0.51 (−1.66, 0.64) | 0.387 |
CAD | 3 | 42.7 | 3.49 | −0.25 (− 0.61, 0.11) | 0.167 |
Type of intervention | |||||
Q10 | 6 | 82.8 | 29.05 | −0.37 (− 0.87, 0.13) | 0.149 |
Q10 + other | – | – | – | – | – |
Dosage of intervention | |||||
≤ 150 | 3 | 48.7 | 3.90 | −0.24 (− 0.64, 0.16) | 0.232 |
> 150 | 3 | 91.8 | 24.25 | −0.53 (−1.64, 0.57) | 0.344 |
Duration of study | |||||
< 8 weeks | 3 | 40.5 | 3.36 | −0.12 (− 0.55, 0.30) | 0.568 |
≥ 8 weeks | 3 | 91.2 | 22.64 | −0.62 (−1.55, 0.31) | 0.195 |
Sample size | |||||
≤ 50 person | 2 | 70.0 | 3.33 | −0.14 (− 0.91, 0.63) | 0.721 |
> 50 person | 4 | 87.8 | 24.52 | −0.48 (−1.17, 0.21) | 0.171 |
HDL-C | |||||
Total | |||||
Type of disease | 5 | 94.7 | 76.05 | 1.30 (0.20, 2.41) | 0.021 |
HF | 2 | 0.00 | 0.02 | −0.04 (−0.43, 0.36) | 0.859 |
CAD | 3 | 95.9 | 48.48 | 2.28 (0.51, 4.05) | 0.011 |
Type of intervention | |||||
Q10 | 5 | 94.7 | 76.05 | 1.30 (0.20, 2.41) | 0.021 |
Q10 + other | – | – | – | – | – |
Dosage of intervention | |||||
≤ 150 | 3 | 78.5 | 9.29 | 0.66 (0.03, 1.30) | 0.041 |
> 150 | 2 | 98.5 | 66.76 | 2.58 (−2.65, 7.81) | 0.334 |
Duration of study | |||||
< 8 weeks | 3 | 62.7 | 5.36 | 0.24 (−0.30, 0.78) | 0.387 |
≥ 8 weeks | 2 | 97.8 | 45.29 | 3.14 (−0.96, 7.24) | 0.133 |
Sample size | |||||
≤ 50 person | 2 | 71.2 | 3.48 | 0.41 (−0.39, 1.20) | 0.315 |
> 50 person | 3 | 97.0 | 67.48 | 2.00 (0.06, 3.93) | 0.043 |
Lp(a) | |||||
Total | 3 | 95.7 | 46.96 | −1.12 (−2.84, 0.61) | 0.204 |
Type of disease | |||||
HF | 1 | – | 0.00 | 0.13 (−0.39, 0.66) | 0.621 |
CAD | 2 | 97.3 | 37.38 | −1.79 (−4.98, 1.40) | 0.272 |
Type of intervention | |||||
Q10 | 3 | 95.7 | 46.96 | −1.12 (−2.84, 0.61) | 0.204 |
Q10 + other | – | – | – | – | – |
Dosage of intervention | |||||
≤ 150 | 2 | 97.3 | 37.38 | −1.79 (− 4.98, 1.40) | 0.272 |
> 150 | 1 | – | 0.00 | 0.13 (−0.39, 0.66) | 0.621 |
Duration of study | |||||
< 8 weeks | 2 | 97.7 | 44.27 | −1.64 (−5.14, 1.87) | 0.360 |
≥ 8 weeks | 1 | – | 0.00 | −0.18 (− 0.69, 0.32) | 0.476 |
Sample size | |||||
≤ 50 person | 1 | – | 0.00 | −3.44 (−4.36, −2.53) | < 0.001 |
> 50 person | 2 | 0.00 | 0.72 | −0.03 (− 0.40, 0.33) | 0.866 |